12:00 AM
Jan 30, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Avastin bevacizumab regulatory update

The U.K.'s NICE issued final guidance recommending against 3 second-line therapies for metastatic colorectal cancer (mCRC). The products are Erbitux cetuximab from Merck KGaA; Avastin bevacizumab from Roche; and Vectibix panitumumab from Amgen. NICE said there were uncertainties in the evidence for the drugs' effectiveness. The decision is in line with a November final appraisal determination (see BioCentury, Dec. 5, 2011).

Erbitux is...

Read the full 299 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >